Tirofiban Reactions 1680, p322 - 2 Dec 2017 Thrombocytopenia A 71-year-old man developed severe thrombocytopenia following administration of tirofiban [route, dosage and time to reaction onset not stated]. The man was diagnosed with an acute coronary syndrome with elevated ST-segment. His relevant medical history included myocardial infarction, hypertension, dyslipidaemia and weaned smoking. He was taking aspirin along with various drugs. He received tirofiban during coronary angiography. He also underwent a stent implantation on the anterior interventricular artery. He was started on precautionary anticoagulation with fondaparinux and combined anti-platelet aggregation with prasugrel and aspirin. On the following day, laboratory investigations showed thrombocytopenia with thrombocyte count of 27 G/L. On day 3, thrombocyte count was decreased to 9 G/L. The man was treated with platelet concentrate unit (PCU) transfusions. On request of the cardiologist, aspirin treatment was also maintained. He was given clopidogrel only when the platelet count elevated beyond 50 G/L. The platelet count decreased again to 7 G/L. On day 10, there was presence of the haemorrhagic mucosal signs. Therefore, he was seen by an internist. Other investigations were found to be negative. Eventually, he was started on prednisone. On day 2 from the start of prednisone, the platelets value was found to be >50 G/L. A tapering of prednisone dose after more than 10 days of treatment showed corticodependence led to increase of dosage, which showed a favourable response. The dose of prednisone was reduced again from day 31 and stopped on day 40 without relapse of thrombocytopenia. Author comment: "We report here the unusual case of a patient with prolonged thrombocytopenia secondary to tirofiban administration during coronary angiography." "We report a case of severe thrombocytopenia secondary to the administration of tirofiban." Christen J-R, et al. Long-lasting thrombocytopenia induced by glycoprotein IIb/IIIa inhibitor. Revue de Medecine Interne 38: 769-773, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1016/j.revmed.2017.05.013 [French; summarised from a translation] - France 803284566 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial